ABSTRACT: Emergence of extensively drug resistant tuberculosis (XDR-TB) has been reported by more than 55 countries. XDR-TB is considered as untreatable and highly fatal disease. In developing countries like India, number of cases of multi-drug resistant tuberculosis (MDR-TB) and XDR-TB are increasing. Emergence of resistance to Isoniazid and Rifampicin, the two most effective and well tolerated agents, coupled with resistance to second line agents pose limited treatment options for XDR-TB. The present minireview provides information about the seriousness of XDR-TB and the drugs available for its treatment. Although considered a fatal disorder, judicious use of combination of drugs, retaining their antimycobacterial activity, can improve the clinical outcome of XDR-TB. Only such an approach can provide some hope for the patients of XDR-TB.
INTRODUCTION
T uberculosis remains a worldwide public health problem despite the fact that the causative organism was discovered more than 100 years ago and highly eff ective drugs and vaccines are made available. According to 13 th annual report of the World Health Organization (WHO), published on world TB day March 24, 2009, an estimation of 9.27 million new case of tuberculosis worldwide, is on record [1] . Around 22 high burden countries collectively account for 80% of the global tuberculosis burden. Highest prevalence in India, with 2.0 million cases is of serious medical concern, in which 1,31,000 cases are of MDR-TB [2] . Almost 10-19% of cases of MDR-TB progress to XDR-TB [3] . A report of an outbreak of XDR tuberculosis in 53 HIV positive patients in South Africa claiming the lives of 52, has been a warning for the global tuberculosis community of the dangers of allowing drug resistance to fl ourish [4] . Emergence of XDR-TB refl ects a failure to implement the measures recommended in WHO's STOP TB strategy.
By the end of 2008, 55 countries have reported the cases of XDR tuberculosis. In the meeting of countries of high burden of MDR or XDR tuberculosis, it was forecasted to achieve the target set out in the global plan to STOP TB. Treatment of 1.4 million cases of MDR and XDR tuberculosis will be required in 27 countries with highest burden, between 2009 and 2015. In higher burden regions, the proportion of MDR tuberculosis cases may 1 to 14% of which XDR may be as high as 21% [2] . Global death rate for 2008 was 20 per 100,000 population and in 2007, it was 27 per 100,000 population [5] . Although, XDR tuberculosis is referred as untreatable and fatal mycobacterial infection, aggressive clinical management may greatly improve the outcome of the disease, which provides hope to many infected patients of XDR-TB. XDR-TB if not treated aggressively is rapidly fatal in HIV infected patients.
Tuberculosis remains a leading cause of death from infectious diseases second only to HIV/AIDS [7] . In MDR-TB, Mycobacterium tuberculosis is resistant to Isoniazid and Rifampicin, two of the most eff ective fi rst line antitubercular drugs. To address the issue of MDR-TB the Revised National Tuberculosis Control Programme (RNTCP), initiated by the Govt. of India, has implemented the DOTS plus strategy. Th e goal of DOTS plus is to prevent further development and spread of MDR-TB. As per the DOTS plus policy, the diagnosis of MDR-TB will be made at the Intermediate Reference Laboratories (ILRs) accredited to perform culture and drug sensitivity testing (DST). Treatment will be initiated at the designated DOTS plus sites. DOTS plus sites shall have qualifi ed staff available to manage the patients using category IV regimen, consisting of second line drugs, given under direct observation (DOT) and standardized follow up protocols including ambulatory DOT after initial short period of in-patient care to stabilize the patient on second line drug regimen. MDR-TB which is resistant to Isoniazid and Rifampicin, the backbone of fi rst line treatment, is more diffi cult and costly to treat. XDR-TB, a subgroup of MDR-TB is an even greater threat to control the disease [4] .
Extensively drug resistant tuberculosis is defi ned as tuberculosis that is resistant to at least Isoniazid and Rifampicin and members of three of the six classes of second line drugs (Table 1) , including one injectable drug (Amikacin, Capreomycin, Kanamycin) [3, 8] Isoniazid and Rifampicin are the anchors of the standard fi rst line therapy [9] .
CAUSES OF XDR-TB:
Mycobacterium tuberculosis, an aerobic acid fact bacilli is the primary cause of tuberculosis. High lipid content of this pathogen accounts for many of its unique clinical characteristics. Other strains could be responsible for XDR TB: M. tuberculosis complex includes four other TB-causing mycobacteria: M. bovis, M. africanum, M. canetti and M. microti [10] .
Extensively drug-resistant tuberculosis (XDR TB) is a rare form of multidrug-resistant tuberculosis (MDR TB) that is transmitted when TB germs are expelled into the air by sneezing or coughing [11] .
Although failure of DOTS plus management at diff erent levels may contribute to the emergence of XDR-TB, other causes are also contributory. Th e unfortunate patient may suff er from primary infection with strain of XDR-TB [6] , a mixed infection or reinfection with resistant strain while on fi rst line therapy [12, 13] , or nosocomial transmission, a well described mode of acquisition of drug resistant tuberculosis in HIV positive patients [13] . Unregulated use of second line drugs can also lead to XDR-TB. Inappropriate use of antimycobacterial agents provide mycobacteria, a new opportunity to develop an additional resistance [1] .
Exposure to fl uroquinolones and injectable antimycobaterial or both for the treatment of bacterial infection may contribute to evolution of resistance to these agents in patients of undiagnosed or inadequately treated tuberculosis.
Drug-resistant TB (MDR or XDR) is more common in people who:
• Do not take their TB medicine regularly • Do not take all of their TB medicines as advised by health personnels. Symptoms of XDR-TB are no diff erent from ordinary or drug-susceptible TB: a cough with thick, cloudy mucus (or sputum), sometimes with blood, for more than 2 weeks; fever, chills, and night sweats; fatigue and muscle weakness; weight loss; and in some cases shortness of breath and chest pain. Symptoms of tuberculosis in other parts of the body depend on the area aff ected. A person with these symptoms does not necessarily have XDR-TB, but they should have thorough investigation. TB patients whose symptoms do not improve after a few weeks of treatment with conventional therapy should inform their clinician or nurse [11] .
Th ere are three main aspects to be considered for the management of XDR-TB:
1. Timely diagnosis of XDR-TB 2. Chemotherapeutic management of XDR-TB 3. Management of HIV/AIDS in coinfected patients
Timely diagnosis of XDR-TB
Delay in the diagnosis of XDR-TB is the main obstacle to an eff ective treatment. Usually diagnosis of tuberculosis is based on smear microscopy and clinical criteria, without sputum culture and drug sensitivity testing. Culture and drug sensitivity testing is at present not possible for all the patients. Government of India has taken serious note of this and initiated the action by increasing the number of centers having these facilities, under RNTCP and STOP TB strategy. Persistent cough and smear positive disease after two months or more of the therapy usually increase the possibility of MDR-TB or XDR-TB. In the context of DOTS, persistent smear positive disease after two months of therapy increases the likelihood of multidrug resistance, by factor of 12 and forms a well established indication for culture and drug sensitivity testing [14] . Conventional methods using liquid and solid medium take about 22 and 68 days respectively. Rapid diagnostic methods like microscopic observation drug susceptibility (MODS) assay, line probe assay, FAST Plaque-Response bacteriophage assay and the micro-colony method have high degree of concordance with drug susceptibility testing reduced the time to 7 days and 1-2 days respectively [15, 16] . Current versions of rapid diagnostic tests however do not detect the resistance to fl uroquinolones and injectable drugs. Rapid diagnostic methods, to detect the resistance of antitubercular drugs including fl uroquinolones and injectable antitubercular agents, are urgently required to be developed.
Management of XDR-TB
Management of XDR-TB should consider the general guidelines given for DOTS plus, under RNTCP and STOP TB strategy by Government of India and WHO. Drug therapy for XDR-TB has to be individualized for a given patient considering culture and sensitivity report.
Empirical therapy based on the treatment and contact history, should be started depending on the results of drug susceptibility tests. Once the results of drug susceptibility tests are available, the regimens should be adjusted accordingly.
1 ATP synthase provide a viable target for antitubercular activity. TMC 207 (formerly R.207910), a diarylquinolone, a selective mycobacterial ATP synthase inhibitor in a dose of 400 mg OD for 2 weeks followed by 200 mg three times a day for 6 weeks in combination with 5 second line drugs, in phase II controlled clinical trial, showed promising results [18] . Patients with localized disease respond well to 18 months of drug therapy after respective thoracic surgery [19] . In patients without conversion of sputum culture after 4 months, drug susceptibility testing should be done with reinforcement of regimen by addition or substitution of two agents that are likely to be eff ective. Adverse events of the drugs should be monitored and properly managed. After completion of the treatment, patients should be followed and screened, clinically and bacteriologically for the recurrence of the disease
Antiretroviral therapy
Presence of HIV/AIDS with XDR-TB is associated with further graver prognosis and increased fatality. Antiretroviral therapy has been associated with improved survival in patients coinfected with MDR mycobacteria. Since signifi cantly higher rate of deaths among these patients has been observed, early initiation of antiretroviral therapy in coinfected patients is considered, regardless of CD4 count [8] . Since antiretroviral and antimycobacterial drugs have many overlapping adverse eff ects (neuropathy, nephrotoxicity, neuropsychiatric eff ects), choice of agents should be carefully decided for regimens. Monitoring of both tuberculosis and HIV infection and new illness is also essential [21] .
Precautionary measures to reduce the disease incidence:
Raise awareness and enhance strategies for TB prevention worldwide by 
